PRF Technologies Ltd. (PRFX)
NasdaqCM: PRFX
· Precio en tiempo real · USD
1.03
-0.17 (-14.17%)
Al cierre: Aug 14, 2026, 3:59 PM
1.01
-1.94%
Fuera de horario: 7:55 PM
Descripción de la empresa
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
PRF Technologies Ltd.
| País | Israel |
| IPO Fecha | 1 sept 2020 |
| Industria | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Empleados | 6 |
| CEO | Mr. Efraim Cohen-Arazi |
Detalles de contacto
Dirección: 65 Yigal Alon St. Tel Aviv-Yafo, Israel | |
| Sitio web | https://www.painreform.com |
Detalles de acciones
| Símbolo bursátil | PRFX |
| Intercambio | NasdaqCM |
| Año fiscal | Jan '25 - Dec '25 |
| Moneda de informe | USD |
| Código CIK | 0001801834 |
| Número CUSIP | n/a |
| Número ISIN | n/a |
| Empleador ID | n/a |
| Código SIC | n/a |
Ejecutivos clave
| Nombre | Posición |
|---|---|
| Dr. Ehud Geller Ph.D. | Executive Chairman |
| Mr. Eyal Broder | Chief Financial Officer |
| Dr. Sigal Aviel eMBA, Ph.D. | Chief Operating Officer |
| Mr. Efraim Cohen-Arazi | Interim CEO & Director |
| Ms. Rita Keynan M.Sc. | Vice President of Pharmaceutical Operations |